Skip to content

Harman Chopra

5 papers in the library · 23 citations · publishing 2024

Papers

Sort Most recent Most cited

Chronic pain education: past, present, and future of psychedelics for the management of chronic pain

Pain Medicine December 10, 2024 Christopher L. Robinson, Pawan Solanki, S Snyder et al.

Known for their capacity to alter perception and consciousness, psychedelics are increasingly being explored for therapeutic applications in treating conditions such chronic pain, major depressive disorder, and post-traumatic stress disorder.1,2 Despite historical stigmas and legal restrictions, recent changes in legislation and the United States Food and Drug Administration (FDA) recognition...

Refractory CRPS pain treated with psilocybin: A case report

Clinical Case Reports September 1, 2024 David S Jevotovsky, Harman Chopra, Court Wing et al. 9 citations

Key Clinical Message Psilocybin shows promise as a treatment for CRPS, offering significant pain relief and functional improvement in a patient with refractory symptoms. This case highlights the need for further research into psilocybin's efficacy and optimal dosing for chronic pain management.

Psilocybin and chronic neuropathic pain: a systematic review

Regional Anesthesia & Pain Medicine August 5, 2024 Harman Chopra, Shravani Durbhakula, Alexander Shustorovich et al. 8 citations

Background/Importance Chronic pain affects many people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain management despite being classified as Schedule I. Objective This systematic review critically evaluates the evidence for psilocybin, a Schedule I substance, in the treatment of chronic pain. The exact purpose of the...

Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report

Clinical Case Reports May 28, 2024 Harman Chopra, Tim Furnish, Monica Verduzco-Gutierrez et al. 6 citations

Key Clinical Message Long‐COVID syndrome lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief after self‐medicating with psilocybin and MDMA. Abstract Long‐COVID, a syndrome persisting after the acute phase of coronavirus disease 2019 (COVID‐19), lacks effective holistic...